Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Rosmarinic acid and myricetin medicament formula and application thereof in treatment of Parkinson disease

A technology of rosmarinic acid and myricetin, which can be used in pharmaceutical formulations, drug combinations, nervous system diseases, etc., can solve problems such as adverse reactions, limited application and promotion, etc., to reduce the generation of reactive oxygen species, and reduce cell mitochondrial membranes. The effect of the drop in potential

Inactive Publication Date: 2010-07-21
QINGDAO UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The purpose of the present invention is to overcome the disadvantages that current traditional anti-PD drugs have some adverse reactions, which seriously limit their application and popularization, and aim to provide a pharmaceutical formula of rosmarinic acid-myricetin compound preparation and its therapeutic effect. Applications in Parkinson's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rosmarinic acid and myricetin medicament formula and application thereof in treatment of Parkinson disease
  • Rosmarinic acid and myricetin medicament formula and application thereof in treatment of Parkinson disease
  • Rosmarinic acid and myricetin medicament formula and application thereof in treatment of Parkinson disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Experiment of rosmarinic acid-myricetin drug formulation exerting neuroprotective effect on MES23.5 dopaminergic cells

[0016] 1. Experimental materials

[0017] (1) cells

[0018] MES23.5 dopaminergic cells were donated by Professor Weidong Le of Baylor College of Medicine in Houston, USA. Set at 37°C, 5% CO 2 cultured in an incubator.

[0019] (2) Drugs and reagents

[0020] Rosmarinic acid is provided by Professor Li Ronggui from the biology teaching and research section of Qingdao University School of Medicine (Li Ronggui, Chinese patent CN1796362, the production process of basil rosmarinic acid), and Dulbecco's modification of Eagle's medium / F12 (Dulbecco's modified Eagle's medium / F12 Medium / F12, DMEM / F12) culture solution (Gibco company) was dissolved with 10 -3 mol / L storage. Diluted to the required concentration of 10 during the experiment -9 mol / L. Myricetin is a product of Sigma Company, dissolved in dimethyl sulfoxide (DMSO) with 10 -3 mo...

Embodiment 2

[0043] Embodiment 2: In vitro toxicity test of rosmarinic acid-myricetin composite preparation drug formulation

[0044] 1. Experimental materials

[0045] (1) Drugs and reagents

[0046] MTT, DMSO.

[0047] (2) Instruments

[0048] Microplate reader: R-T-2100C, Shenzhen Redu Company.

[0049] 2. Experimental method

[0050] Take MES23.5 dopaminergic cells in the logarithmic growth phase, pipette to make a single cell suspension, centrifuge, and dilute to 2×10 with complete medium 5 cells / ml cell suspension, inoculated in 96-well plate with 200 μl per well, placed at 37°C, 5% CO 2 cultured in an incubator. After the cell confluency reaches 70-80%, replace with serum-free medium and drug treatment, add rosmarinic acid (10 -9 mol / L) and myricetin (10 -10 mol / L), after incubating MES23.5 dopaminergic cells for 24 hours, the negative control group was only replaced with serum-free medium, and 6 replicate wells were set up for each concentration; 4 hours before the end of c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a rosmarinic acid and myricetin medicament formula and application thereof in treatment of Parkinson disease. The medicament formula of the compound preparation comprises rosmarinic acid and myricetin of which the molar concentration ratio is 10:1. The medicament is used for neuroprotection. When 10-9 mol / L of the rosmarinic acid is mixed with 10-10 mol / L of the myricetin, the reduction of MES23.5 dopaminergic cell survival rate induced by the neurotoxin 6-hydroxydopamine is relieved; the reduction of membrane potential of cell mitochondrion induced by the neurotoxin 6-hydroxydopamine is relieved and the generation of reactive oxygen substances is reduced; and the medicament has anti-oxidative stress. The medicament can prevent the MES23.5 membrane potential dopaminergic cells from suffering from the damage of neurotoxin 6-OHDA, has safety and less side effect, and has important application prospect and value to be developed into a novel natural medicament for resisting the Parkinson disease.

Description

Technical field: [0001] The invention relates to a rosmarinic acid-myricetin medicinal formula and its application in the treatment of Parkinson's disease, in particular to a rosmarinic acid-myricetin compound medicinal formula and its effect on dopaminergic effects in the treatment of Parkinson's disease. Use of neurons for neuroprotection. It belongs to the field of medical technology. Background technique: [0002] Neurodegenerative diseases are serious brain diseases that plague the middle-aged and elderly people in modern society. Parkinson's disease (PD) ranks second in incidence after Alzheimer's disease, which ranks first. Whether it is from the perspective of sociology or market economy, PD has become a major social problem that affects the health and quality of life of the population in my country and the world, and hinders the sustainable development of the economy. The main pathological changes of PD are the loss of dopaminergic neurons in the substantia nigra ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/216A61P25/16A61P39/06
Inventor 谢俊霞姜宏李荣贵宋宁杜婷婷
Owner QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com